ABSTRACT

This article provides a critical evaluation of the analytical methods employed for the concurrent measurement of rosuvastatin calcium (ROS), fenofibrate (FEN), and ezetimibe (EZE) in pharmaceutical formulations and biological specimens. Focus is given to UV spectrophotometry, HPLC, and LC-MS/MS methods. ROS, a powerful HMG-CoA reductase inhibitor, is often administered in combination with FEN and EZE for managing high-risk individuals who fail to reach lipid targets with monotherapy. Several spectrophotometric techniques based on simultaneous equations, first-order derivatives, and various detection wavelengths have been described for ROS and FEN. Numerous RP-HPLC procedures using varying mobile phases, flow rates, and detection settings are available for ROS and FEN estimation. For ROS and EZE, methods involving HPLC, UPLC, and LC-MS/MS have been developed utilizing diverse columns, mobile phases, and detection systems. The review also introduces Green Analytical Chemistry (GAC) principles and evaluates the environmental sustainability of these methods using AGREE and GAPI tools. Emphasis is placed on the adoption of environmentally safer approaches without compromising analytical performance. Keywords: Rosuvastatin, Fenofibrate, Ezetimibe, UV spectrophotometry, HPLC, LC– MS/MS, Green Analytical Chemistry, AGREE, GAPI
Publication date: 01/07/2026

https://www.ijbpas.com/pdf/2026/July/MS_IJBPAS_2026_10337.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.7.10337